Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Janssen Research & Development, LLC
Janssen Research & Development, LLC
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
Pfizer
GlaxoSmithKline
European Myeloma Network B.V.
Wake Forest University Health Sciences
Massachusetts General Hospital
Dana-Farber Cancer Institute
BioLineRx, Ltd.
Pfizer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Washington University School of Medicine
University of Washington
Memorial Sloan Kettering Cancer Center
GlaxoSmithKline
National Cancer Institute (NCI)
Weill Medical College of Cornell University
GlaxoSmithKline
City of Hope Medical Center
University of Chicago
Weill Medical College of Cornell University
GlaxoSmithKline
GlaxoSmithKline
GlaxoSmithKline